We serve Centralite II CAS:611-92-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Product Name：Centralite II
Synonym: N,N'-Dimethylcarbanilide
1,3-Dimethyl-1,3-Diphenylurea
N,N`-Dimethyl-N,N`-Diphenylurea
CAS NO.：611-92-7
Chemical & Physical Properties
Density: 1.161±0.06 g/cm3
Boiling Point: 350.0±11.0 °C at 760 mmHg
Melting Point: 120-122 °C(lit.)
Molecular Formula: C15H16N2O
Molecular Weight: 240.300
Flash Point: 142.6±11.6 °C
Exact Mass: 240.126266
PSA: 23.55000
LogP: 2.52
Vapour Pressure: 0.0±0.8 mmHg at 25°C
Index of Refraction: 1.639
Water Solubility: Very slightly soluble (0.13 g/L) (25 ºC
Specification
Appearance: White to light yellow crystal powder
Assay: ≥98.0%
Volatile: ≤0.2%
Application
Stabilizers for smokeless explosives, nitrates and smokeless fuels, as well as intermediates for fine chemicals.
Package and Storage
25kg/bag, store at room temperature away from light.
Contact us for information like Centralite II chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N`-Dimethyl-N,N`-Diphenylurea physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Centralite II Use and application,N,N’-Dimethylcarbanilide technical grade,usp/ep/jp grade.
Related News: With the continuous accumulation of the API industry and the increasing maturity of the market, competition in China’s API industry will become increasingly fierce.2-methyl-6-(3-methylbut-2-en-1-yl)-1-((4S,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl)-3H-carbazole-3,4(9H)-dione manufacturer They have also voiced frustrations about patients from mainland China hiding their travel and medical history, potentially endangering other patients.5-amino-2′-bromobiphenyl-3-carboxylic acid methyl ester supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.tetramethyl 2,3-dihydropentalene-1,3a,4,6a(1H,6H)-tetracarboxylate vendor The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%.
